Pharmaceutical Technology

APRIL 28, 2023

In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.

Diabetes 52

Diabetes Dosage Labelling Compounding 52

Express Pharma

OCTOBER 16, 2024

The CRO sector in India, growing at a compound annual growth rate (CAGR) of 10.75 billion by 2029 (3). Courtesy of contract research organisations (CROs), contract manufacturing organisations (CMOs), and contract development and manufacturing organisations (CDMOs), India’s life sciences sector is rising steadily. billion by 2030 (2).

Biosimilars 103

Biosimilars Compounding Pharmaceutical Companies Pharmaceutical Companies 103

PharmaShots

FEBRUARY 22, 2023

In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). Hence, it needs to protect its patent as Trulicity patents are very vital to the company’s business as a whole.

Diabetes 64

Diabetes Compounding Dosage Communication 64

pharmaphorum

DECEMBER 20, 2022

He said ensifentrine will “change the treatment paradigm” for COPD by providing bronchodilation and anti-inflammatory properties in one compound. Shares in Verona popped on the news, rising more than 40% to approach $19.50 and drive the company’s market cap to almost $1.5

Compounding 59

Compounding 59

European Pharmaceutical Review

JANUARY 18, 2024

Insomnia market Dual orexin receptor antagonists (DORAs) [dual orexin receptor antagonists (DORAs)]… offer a new mechanism of action [in treating insomnia]” Across the seven major markets, the insomnia market is anticipated to grow at a compound annual growth rate (CAGR) of 2.6 percent from $3.2 billion in 2022 to $4.1

Drug Pricing 98

Drug Pricing Biosimilars Compounding 98

pharmaphorum

AUGUST 31, 2022

The sheer number of treatment candidates moving through the pipeline has seen a recent report by Polaris Market Research predicts that the market will grow at a compound annual growth rate of 17.0% from 2021 to 2029. FDA backing.

Compounding 98

Compounding Vaccines 98

Pharmaceutical Technology

JANUARY 10, 2023

billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. billion in 2029, although its sales growth is likely to continue beyond 2029. GlobalData expects that the T2D market will see significant growth from 2019–29, with the 9MM having a total of $45.9

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

Pharmaceutical Technology

FEBRUARY 3, 2023

According to GlobalData’s patient-based forecasts, infliximab biosimilars were anticipated to grow a notable compound annual growth rate (CAGR) of 14% from 2019 to 2029 in Remicade’s leading immunology indications, CD and UC.

Biosimilars 52

Biosimilars Compounding 52

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

Each phase-in policy allows eligible manufacturers to build up in a stepwise manner to the 10% and 20% applicable discounts by 2029 and 2031, respectively. A “specified drug” means, for 2021, an applicable drug that is produced, prepared, propagated, compounded, converted, or processed by a specified manufacturer.

Labelling 105

Labelling Drug Pricing Compounding Payment Processing 105

Viseven

JANUARY 15, 2025

in 2029 , with a compound annual growth rate of 27.9%. Life sciences companies can use AI to analyze vast amounts of data and identify drug targets, design small molecules, generate synthesis pathways for chemical compounds, and predict drug properties. The global market for AI in life sciences is projected to reach $33.5b

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Compounding Communication 52

European Pharmaceutical Review

JANUARY 21, 2025

billion in 2029 at a compound annual growth rate (CAGR) of 7.9 Molecular spectroscopy As one of the main types of spectroscopy technology, the molecular spectroscopy marke t is anticipated to expand at a compound annual growth rate (CAGR) of 9.1 It will grow to $31.77 percent between 2024 and 2025.

Compounding 59

Compounding Drug Development 59